US-based AVEO Oncology, an LG Chem (KRX:051910) company, announced on Wednesday that the 20mg/kg dose of ficlatuzumab has been chosen for the combination arm of the Phase 3 registrational FIERCE-HN clinical trial following the planned first interim analysis.
The ongoing FIERCE-HN trial continues to enrol patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) and aims to recruit 410 to 500 patients.
The global, multicentre, randomised, double-blind, placebo-controlled Phase 3 clinical trial is evaluating ficlatuzumab in combination with ERBITUX (cetuximab), an anti-epidermal growth factor receptor (EGFR) antibody, as compared to placebo plus cetuximab, in patients with HPV-negative R/M HNSCC.
Ficlatuzumab is AVEO's investigational antibody that targets hepatocyte growth factor (HGF).
FDA grants Fast Track status to SIM0505 for platinum‑resistant ovarian cancer
AstraZeneca reports positive Phase III data for Imfinzi and Imjudo in liver cancer
Mary's Medicinals to participate in CMS trial programme with cannabinoid-based wellness products
Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development
Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal
Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
GXO appointed to manage NHS England bowel cancer home testing kits